Research library

A

grade

Tesamorelin significantly reduces visceral fat and improves lipid levels in HIV patients, but the long-term clinical implications of these changes are not fully understood.

-24 +/- 41 cm(2) VAT reduction in tesamorelin vs 2 +/- 35 cm(2) in placebo at 26 wk, P < 0.001.

summary

D

grade

Tesamorelin may help reduce visceral fat and improve body image in patients with HIV-related lipodystrophy, but cost and long-term safety data are concerns.

Not reported in abstract.

summary

A

grade

The TRIUMPH study is examining whether tesamorelin combined with exercise can improve physical function in older adults living with HIV, but results are not yet available.

summary

A

grade

This pilot study found no significant effects of low-dose tesamorelin on cognitive function or brain connectivity after 10 weeks of treatment in adults with mild cognitive impairment.

Not reported in abstract.

summary

A

grade

Tesamorelin was associated with significant reductions in visceral fat and liver fat in HIV-infected patients over 6 months, but the clinical importance of these findings needs further investigation.

-34 cm2 mean change in visceral adipose tissue with tesamorelin vs 8 cm2 with placebo; P=0.005.

summary

A

grade

This study highlights significant relationships between IGF-1, IGFBPs, and the severity of nonalcoholic fatty liver disease, suggesting complex interactions that warrant further investigation.

Not reported in abstract.

summary

B

grade

Acromegaly patients showed lower rates of hepatic steatosis compared to metabolically matched controls, suggesting a possible protective effect of growth hormone.

CAP scores: 241.8 ± 50.0 dB/m in acromegaly patients, 281.7 ± 61.2 dB/m in metabolically matched controls, p < 0.001.

summary

A

grade

The TRIUMPH study will explore the effects of tesamorelin combined with exercise on physical function in older adults living with HIV, but results are not yet available.

summary

A

grade

This pilot study found no significant changes in cognitive function or brain connectivity with low-dose tesamorelin treatment over 10 weeks, highlighting the need for larger studies to confirm any potential effects.

Not reported in abstract.

summary

A

grade

Neither maraviroc nor metformin significantly reduced liver fat percentage in adults with HIV and NAFLD compared to standard antiretroviral therapy.

Mean PDFF at week 48 was 12.9% (SD 9.0), n=82.

summary

A

grade

Tesamorelin may reduce visceral fat and improve lean body mass in adults with HIV-associated lipodystrophy, but the clinical significance of these changes remains uncertain.

MD=-27.71 cm² visceral adipose tissue reduction, 95% CI [-38.37, -17.06]; P<0.001

summary

D

grade

Not reported in abstract.

summary

D

grade

The paper emphasizes the need for tailored approaches to manage MASLD in people with HIV due to its aggressive nature compared to HIV-negative individuals.

summary

D

grade

Several medications, including tesamorelin, are disproportionately associated with carpal tunnel syndrome, warranting careful evaluation of pharmacological history in affected patients.

tesamorelin ROR=20.7, 95% CI=13.7-31.3.

summary